Generic drugmakers hire new lobbyist


The group spent nearly $1.1 million to lobby the government in the first half of this year, on pace to bypass last year’s expenditures of more than $1.9 million, according to federal records.

Ralph Neas, GPhA’s president and chief executive, said Wilson will “round out and strengthen” the group’s “bipartisan legislative efforts.”

“Heidi’s familiarity with the nuance of our health policy landscape, particularly her Congressional and private sector experience, makes her well positioned to convey the GPhA message of safety and cost savings from generic therapies to the Congress,” he said in a statement.

This story was updated at 1:50 p.m.